Speaker Profile
Ph.D., Assistant Professor, City of Hope
Biography
Dr. Nath is a cancer biologist with expertise in both experimental and computational biology. At City of Hope, Dr. Nath leads a collaborative research team that investigates the potential of AIML in enhancing cancer patient outcomes. Through the integration of bioinformatics and AIML tools, his research aims to unravel the underlying mechanisms of tumor progression and establish cutting-edge biomarkers for improving the clinical outcomes of patients with cancer. His research employs multi-omics approaches to identify the drivers of tumor evolution and the subsequent development of drug resistance. Dr. Nath aspires to translate research findings into clinical impact, notably contributing to upcoming clinical trials in lung and breast cancer that will implement novel AI-guided biomarkers. Dr. Nath currently is a principal investigator (PI) of an ARPA-H grant, an NIH U01 grant, a PHASE ONE foundation grant, a JKTG foundation grant, and co-investigator of an ARPA-H and California Institute for Regenerative Medicine (CIRM) grant.
Session Abstract – PMWC 2026 Silicon Valley
Track Chairs:
Gad Getz, Broad Institute & Alex Morgan, Khosla Ventures
PMWC Award Ceremony
• Greg Brockman, President & Co-Founder, OpenAI
• Steve Wozniak, Co-Founder, Apple
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, President & Co-Founder, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Foundation Models for Human Biology: Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
Systems Integration for Drug Discovery and AI
• Hugo Lam, Genentech
Interpretable AI Models for Multi-Modal Biomarker Discovery in Drug Development
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Chair: Rajat Roy, PATHOMIQ INC
• Shivanni Kummar, MD, OHSU
Can AI Really Create the Next Blockbuster Drug? Closing the Loop from Discovery to Development
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI: From Genomic Data to Therapeutic Insights
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug?
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
